Mechanism and history of evolution of symbiotic HIV strains into lethal pandemic strains: The key event may have been a 1927 trial of pamaquine in Leopoldville (Kinshasa), Congo

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 838-848

  Parris, George E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; CHLOROQUINE; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PAMAQUINE; PLASMOQUINE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RETROVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SYMBIOSIS; T LYMPHOCYTE; VIRUS LOAD; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINOQUINOLINES; ANIMALS; CLINICAL TRIALS; CONGO; DISEASE OUTBREAKS; EVOLUTION, MOLECULAR; HIV; HIV INFECTIONS; HUMANS; MALARIA; MODELS, ANIMAL; PRIMATES; SYMBIOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PRIMATES;

EID: 34547844168     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.073     Document Type: Article

References (93)

1. Keele B.F., Van Heuverswyn F., Li Y., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313 (2006) 523-526
2. Marx P.A. Unsolved questions over the origin of HIV and AIDS: although HIV originated in nonhuman primates, we do not understand how it became a successful pathogen in its human host. ASM News 71 (2005) 15-20
3. Marx P.A., Alcabes P.G., and Drucker E. Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa. Philos Trans R Soc Lond B - Biol Sci 356 (2001) 911-920
4. Marx P.A., Apetrei C., and Drucker E. AIDS as a zoonosis? Confusion over the origin of the virus and the origin of the epidemics. J Med Primatol 33 (2004) 220-226
5. Korber B., Muldoon M., Theiler J., et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288 (2000) 1789-1796
6. Burr T., Hyman J.M., and Myers G. The origin of acquired immune deficiency syndrome: Darwinian or Lamarchian?. Philos Trans R Soc Lond B - Biol Sci 356 (2001) 877-887
7. Peeters M., Courgnaud V., Abela B., et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis 8 (2002) 451-457
8. Wolfe N.D., Switzer W.M., Carr J.K., et al. Naturally acquired retrovirus infections in central African hunters. Lancet 363 (2004) 932-937
9. Kalish M.L., Wolfe N.D., Ndongmo C.B., et al. Central African hunters exposed to simian immunodeficiency virus. Emerg Infect Dis 11 (2005) 1928-1930
10. Locher C.P., Witt S.A., Herndier B.G., et al. Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons. J Virol 77 (2003) 77-83
11. Apetrei C., Becker J., Metzger M., et al. Potential for HIV transmission through unsafe injections. AIDS 20 (2006) 1074-1076
12. Yuste E., López-Gali{dotless}́ndez C., and Domingo E. Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol 74 (2000) 9546-9552
13. Yuste E., Sánchez-Palomino S., Casado C., Domingo E., and López-Gali{dotless}́ndez C. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 73 (1999) 2745-2751
14. Hrdy D.B. Cultural practices contributing to the transmission of human immunodeficiency virus in Africa. Rev Infect Dis (Chicago) 9 (1987) 1109-1119
15. Parris G.E. Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. Med Hypotheses 62 (2004) 354-357
16. Parris G.E. AIDS: caused by development of resistance to drugs in a non-target intracellular parasite. Med Hypotheses 68 (2007) 151-157
17. Van den Branden F., and Henry M.E. Nouvelle medication du paludisme par plasmoquine. Bull Soc Pathol Exot 12 October (1927) 728-734
18. D'Alessandro U., and Buttiens H. History and importance of antimalarial drug resistance. Trop Med Int Health 6 (2001) 845-848
19. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., and Roederer M. Massive infection and loss of memory CD+ T-cells in multiple tissues during acute SIV infection. Nature 434 (2005) 1093-1097
20. Al-Olayan E.M., Williams G.T., and Hurd H. Apoptosis in the malaria protozoan, Plasmodium berghei: a possible mechanism for limiting intensity of infection in the mosquito. Int J Parasitol 32 (2002) 1133-1143
21. Fujimoto I., Pan J., Takizawa T., and Nakanishi Y. Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages. J Virol 74 (2000) 3399-3403
22. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 17 (2005) 366-373
23. Li Q., Duan L., Estes J.D., et al. Peak SIV replication in resting memory CD4+ T-cells depletes gut lamina propria CD4+ T-cells. Nature 434 (2005) 1148-1152
24. Levine A.D., and Fiocchi C. Regulation of life and death in lamina propria T-cells. Semin Immunol 13 (2001) 195-199
25. Grossman Z., Meier-Schellersheim M., Paul W.E., and Picker L.J. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 12 (2006) 289-295
26. Krambovitis E., and Spandidos D.A. HIV-1 infection: Is it time to reconsider our concepts?. Int J Mol Med 18 (2006) 3-8
27. Paris GE. HIV-infection of CD4+ T-cells enhances their effectiveness against hepatocytes infected with malaria parasites. Med Hypotheses 2006;(Nov 10).
28. Pessler F., and Hernandez N. The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-d-benzimidazole-resistant short transcripts in vitro. J Biol Chem 273 (1998) 5375-5384
29. Keen N.J., Churcher M.J., and Karn J. Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex. EMBO J 16 (1997) 5260-5272
30. Bohan C.A., Kashanchi F., Ensoli B., Buonaguro L., Boris-Lawrie K.A., and Brady J.N. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 2 (1992) 391-407
31. Kwak Y.T., Ivanov D., Guo J., Nee E., and Gaynor R.B. Role of the human and murine cyclin T proteins in regulating HIV-1 Tat-activation. J Mol Biol 288 (1999) 57-69
32. Bagasra O., Farzadegan H., Seshamma T., Oakes J.W., Saah A., and Pomerantz R.J. Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS 8 (1994) 1669-1674
33. Marino-Ramirez L., and Jordan I.K. Transposable element derived DNaseI-hypersensitivity sites in the human genome. Biol Direct 1 (2006) 20
34. Sharp P.M., Bailes E., Robertson D.L., Gao F., Beer B.E., and Hahn B.H. Origins and evolution of AIDS viruses. Biol Bull 196 (1999) 338-342
35. Sharp P.M., Bailes E., Gao F., Beer B.E., Hirsch V.M., and Hahn B.H. Origins and evolution of AIDS viruses: estimating the time-scale. Biochem Soc Trans 28 (2000) 275-282
36. Brandner G., Kloft W.J., Schlager-Vollmer C., Platten E., and Neumann-Opitz P. Preservation of HIV infectivity during uptake and regurgitation by the stable fly, Stomoxys calcitrans L. AIDS-Forsch 7 (1992) 253-256
37. Kun J.F. Regulation of nitrogen monoxide production in human malaria. Redox Rep 8 (2003) 289-291
38. Berliner R.W., Earle Jr. D.P., Taggart J.V., et al. Studies on the chemotherapy of the human malarias. VII. The antimalarial activity of pamaquine. J Clin Invest 27 (1948) 108-113
39. Yi A.-K., Peckham D.W., Ashman R.F., and Krieg A.M. CpG DNA rescues B cells from apoptosis by activating NFkB and preventing mitochondrial membrane disruption via a chloroquine-sensitive pathway. Int Immunol 11 (1999) 2015-2024
40. Yin F., Guo M., and Yao S. Kinetics of DNA binding with chloroquine phosphate using capacitive sensing method. Biosens Bioelectron 19 (2003) 297-304
41. Allison J.L., O'Brien R.L., and Hahn F.E. DNA: reaction with chloroquine. Science 149 (1965) 1111-1113
42. O'Brien R.L., Olenick J.G., and Hahn F.E. Reactions of quinine, chloroquine and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions. Proc Natl Acad Sci USA 55 (1966) 1511-1517
43. Cohen S.N., and Yielding K.L. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci USA 54 (1965) 521-527
44. Ciak J., and Hahn F.E. Chloroquine: mode of action. Science 151 (1966) 347-349
45. 2+ dependence and differential half-site recognition. J Biol Chem 266 (1991) 252-260
46. Bai S., Liu H., Chen K.H., et al. NF-kappaB-regulated expression of cellular FLIP protects rheumatoid arthritis synovial fibroblast from tumor necrosis factor alpha-mediated apoptosis. Arthritis Rheum 50 (2004) 3844-3855
47. Todaro M., Zerilli M., Triolo G., et al. NF-κB protects Behcet's disease T cells against CD95-induced apoptosis upregulating antiapoptotic proteins. Arthritis Rheum 52 (2005) 2179-2191
48. Chugh P., Matta H., Schamus S., et al. Constitutive NF-κB activation, normal Fas-induced apoptosia, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci USA 102 (2005) 12885-12890
49. Snow A.L., Lambert S.L., Natkunam Y., Esquivel C.O., Krams S.M., and Martinez O.M. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. Immunology 177 (2006) 3283-3293
50. Bauer A., Villunger A., Labi V., Fischer S.E., and Strasser A. The NF-κB regulator Bcl-3 and BH3-only proteins BIM and Puma control the death of activated T cells. Proc Natl Acad Sci USA 103 (2006) 10979-10984
51. Zender L., Hutker S., Mundt B., et al. NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Hepatology 41 (2005) 280-289
52. Savarino A., Boelaert J.R., Cassone A., Majori G., and Cauda R. Effects of chloroquine on viral infections: An old drug against today's diseases?. Lancet Infect Dis 3 (2003) 722-727
53. Vincent M.J., Bergeron E., Benjannet S., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. J Virol 2 (2005) 69
54. Munkanta M., Handema R., Kasai H., et al. Predominance of three NF-kappa-B binding sites in the long terminal repeat region of HIV type 1 subtype C isolates from Zambia. AIDS Res Hum Retrov 21 (2005) 901-906
55. Dandekar D.H., Ganesh K.N., and Mitra D. HIV-1 Tat directly binds to NF-kappa-B enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res 32 (2004) 1270-1278
56. Edmonson P., Murphey-Corb M., Martin L.N., et al. Evolution of a simian immunodeficiency virus pathogen. J Virol 72 (1998) 405-414
57. Ilvinskii P.O., Simon M.A., Czajak S.C., Lackner A.A., and Desrosiers R.C. Induction of AIDS by simian immunodeficiency virus lacking NF-kappa-B and SP-1 binding elements. J Virol 71 (1997) 1880-1887
58. DeLuca C., Kwon H., Pelletier N., Wainberg M.A., and Hiscott J. NF-kappaB protects HIV-infected myeloid cells from apoptosis. Virology 244 (1998) 27-38
59. Copeland K.E., Chen Z., Fiebig M., et al. Identification of mutations in proviral long terminal repeats of HIV type 1-infected subjects naive to drug therapy. AIDS Res Hum Retrov 20 (2004) 1019-1021
60. Lemey P., Derdelinckx I., Rambaut A., et al. Molecular footprint of drug-selective pressure in human immunodeficiency virus transmission chain. J Virol 79 (2005) 11981-11989
61. Bezemer D., de Ronde A., Prins M., et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 11 (2006) 173-178
62. Tong-Starksen S.E., Welsh T.M., and Peterlin B.M. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol 145 (1990) 4348-4354
63. Arien K.K., Abraha A., Quinones-Mateu M.E., Kestens L., Vanham G., and Arts E.J. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 79 (2005) 8979-8990
64. Song R.J., Chenine A.L., Rasmussen R.A., et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C env. J Virol 80 (2006) 8729-8738
65. Kurata S., and Yamamoto N. Glucocorticoid can reduce the transcriptional activation of HIV-1 promoter through reduction of active NF-kappaB. J Cell Biochem 76 (1999) 13-19
66. Qian J., Bours V., Manischewitz J., Blackburn R., Siebenlist U., and Golding H. Chemically selected subclones of the CEM cell line demonstrate resistance to HIV-1 infection resulting from a selective loss of NF-kappaB DNA binding proteins. J Immunol 152 (1994) 4183-4191
67. Perfettini J.L., Roumier T., Castedo M., et al. NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J Exp Med 199 (2004) 629-640
68. Hashimoto F., Oyaizu N., Kalyanaraman V.S., and Pahwa S. Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Blood 90 (1997) 745-753
69. Savarino A., Gennero L., Chen H.C., et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 15 (2001) 2221-2229
70. Savarino A., Lucia M.B., Rastrelli E., et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35 (2004) 223-232
71. Savarino A., Di Trani L., Donatelli I., Cauda R., and Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6 (2006) 67-69
72. Chu V.C., and Whittaker G.R. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci USA 101 (2004) 18153-18158
73. Apostolov K., Barker W., Galpin S.A., Habib N.A., Wood C.B., and Kinchigton D. Syncytia formation in HIV-1 infected cells is associated with an increase in cellular oleic acid. FEBS Lett 250 (1989) 241-244
74. Heeney J.L., Dalgleish A.G., and Weiss R.A. Origins of HIV and the evolution of resistance to AIDS. Science 313 (2006) 462-466
75. Lemey P., Pybus O.G., Wang B., Saksena N.K., Salemi M., and Vandamme A.M. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA 100 (2003) 6588-6592
76. Rosenzweig M., Connole M., Forand-Barabasz A., Tremblay M.P., Johnson R.P., and Lackner A.A. Mechanisms associated with thymocyte apoptosis induced by simian immunodeficiency virus. J Immunol 165 (2000) 3461-3468
77. Bahbouhi B., Landay A., and Al-Harthi L. Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood 103 (2004) 4581-4587
78. Guillemard E., Jacquemot C., Aillet F., Schmitt N., Barre-Sinoussi F., and Israel N. Human immunodeficiency virus 1 favors the persistence of infection by activating macrophages through TNF. Virology 329 (2004) 371-380
79. Parlato S., Santini S.M., Lapenta C., et al. Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of chronically infected cells through a massive fas-mediated autocrine suicide of uninfected cells. Cell Death Differ 7 (2000) 37-41
80. Regamey N., Harr T., Battegay M., and Erb P. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. AIDS Res Hum Retrov 15 (1999) 803-810
81. Korant B.D., Strack P., Frey M.W., and Rizzo C.J. A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv Exp Med Biol 436 (1998) 27-29
82. Liu H., Ma Y., Pagliari L.J., et al. TNF-alpha-induced apoptosis of macrophages following inhibition of NF-kappa B: a central role for disruption of mitochondria. J Immunol 172 (2004) 1907-1915
83. Schindler M., Munch J., Kutsch O., et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125 (2006) 1055-1067
84. Olivetta E., and Federico M. HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis. Exp Cell Res 312 (2006) 890-900
85. Ndolo T., Dhillon N.K., Nguyen H., Guadalupe M., Mudryj M., and Dandekar S. Simian immunodeficiency virus Nef protein delays the progression of CD4+ T cells through G1/S phase of the cell cycle. J Virol 76 (2002) 3587-3595
86. Rasola A., Gramaglia D., Boccaccio C., and Comoglio P.M. Apoptosis enhancement by the HIV-1 Nef protein. J Immunol 166 (2001) 81-88
87. Oiao X., He B., Chiu A., Knowles D.M., Chadburn A., and Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 7 (2006) 302-310
88. Olivetta E., Percario Z., Fiorucci G., et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol 170 (2003) 1716-1727
89. Azad A.A. Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells?. Biochem Biophys Res Commun 267 (2000) 677-685
90. Sinton J.A., Smith S., and Pottinger D. Studies in malaria with special reference to treatment. XII. Further researches into the treatment of chronic benign tertian malaria with plasmoquine and quinine. Indian J Med Res 17 (1930) 793-814
91. Schmidt L.H., Alexander S., Allen L., and Rasco J. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and 1 isomers. Antimicrob Agents Chemother 12 (1977) 51-60
92. Georges-Courbot M.C., Lu C.Y., Makuwa M., et al. Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus. J Virol 72 (1998) 600-608
93. Marx P.A., Li Y., Lerche N.W., et al. Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a west African pet sooty mangabey. J Virol 65 (1991) 4480-4485